Opportunity Scan

Diamonds in the Rough

Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XBI constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.

19 in diamond zone145 scored

Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.

Alpha Quadrant — Valuation × Technical Exhaustion

X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.

Accumulation (MFI ≥ 55)Neutral flowDistribution (MFI ≤ 45)Diamond-zone ring

◆ Diamond in the RoughCheap + oversold. Deep value in a technically exhausted state — the prime target.

Fairly Valued WinnerCheap + extended. Strong action backed by earnings, but late for new entries.

Value TrapExpensive + beaten down. Falling yet still richly valued — structurally suspect.

Momentum DarlingExpensive + extended. Crowded leaders with mean-reversion risk.

Diamond Candidates

Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.

#
1	IRWD	Ironwood Pharmaceuticals, Inc. - Class A	66.3	9.97%	2.79	55	+18.33%	58	distress
2	BCRX	BioCryst Pharmaceuticals Inc	61.9	10.85%	1.57	53	+1.97%	62	distress
3	PTCT	PTC Therapeutics, Inc.	57.0	15.84%	0.64	50	-5.35%	55	safe
4	EBS	Emergent Biosolutions, Inc.	54.8	8.58%	0.09	46	-23.37%	39	grey
5	UTHR	United Therapeutics Corp	52.6	7.39%	0.31	48	-2.11%	55	safe
6	NVAX	Novavax Inc	52.5	28.89%	0.75	68	+21.65%	73	distress
7	RIGL	Rigel Pharmaceuticals Inc. (New)	51.0	15.28%	0.89	67	+25.34%	59	safe
8	NBIX	Neurocrine Biosciences Inc	50.6	4.07%	0.33	38	-13.09%	37	safe
9	INCY	Incyte Genomics Inc	45.8	7.32%	0.34	68	+10.24%	60	safe
10	EXEL	Exelixis Inc	43.8	6.59%	0.77	60	+1.63%	51	safe
11	GILD	Gilead Sciences Inc	42.7	4.89%	0.83	70	+13.56%	81	safe
12	MDXG	MiMedx Group, Inc	41.0	7.86%	0.20	55	+2.36%	52	safe
13	ADMA	ADMA Biologics, Inc.	39.1	8.70%	0.41	57	+15.99%	43	safe
14	ALKS	Alkermes Inc. plc	38.7	2.76%	0.29	48	-6.93%	61	safe
15	ALNY	Alnylam Pharmaceuticals, Inc.	38.6	2.44%	0.22	49	-11.95%	61	safe

Short-Squeeze Watch

Constituents with the highest composite squeeze score — heavy short interest meeting price support.

#
1	SMMT	Summit Therapeutics Inc. Common Stock	94.5	26.36%	8.86	-3.54%	critical
2	SANA	Sana Biotechnology, Inc. Common Stock	93.3	25.41%	16.33	+26.93%	critical
3	ZBIO	Zenas BioPharma, Inc. Common Stock	93.3	40.32%	13.83	+9.25%	critical
4	IBRX	ImmunityBio, Inc. Common Stock	93.2	35.04%	14.49	+12.97%	critical
5	INBX	Inhibrx Biosciences, Inc. Common Stock	92.9	35.96%	15.64	+48.55%	critical
6	PRME	Prime Medicine, Inc. Common Stock	92.7	34.63%	12.90	+24.92%	critical
7	BBOT	BridgeBio Oncology Therapeutics, Inc. Common Stock	91.2	23.49%	20.77	+4.11%	critical
8	SION	Sionna Therapeutics, Inc. Common Stock	90.1	50.74%	6.79	-86.42%	critical
9	VOR	Vor Biopharma Inc. Common Stock	89.9	54.85%	8.32	+23.64%	critical
10	AVBP	ArriVent BioPharma, Inc. Common Stock	89.4	25.67%	13.92	-1.60%	critical
11	BEAM	Beam Therapeutics Inc. Common Stock	89.0	29.47%	11.31	+21.93%	critical
12	TYRA	Tyra Biosciences, Inc. Common Stock	88.3	27.66%	17.83	-13.32%	critical

Market cap, valuation, and short-interest metrics are joined to the latest XBI holdings snapshot; each ticker links to its full quote and analysis page.